Patients with tumor cell PD‐L1 expression ≥1% treated with nivolumab plus chemotherapy continued to demonstrate improvement in median OS (15.0 months [95% CI 11.9–18.6]) versus those treated with chemotherapy (9.1 months [95% CI 7.7–10.0]) with a 41% reduction in the risk of death (HR, 0.59 [95% CI 0.46–0.76]) (Figure 1A). The gene discussed is CD274; the disease is neoplasm.